GNFT

Genfit S.A. (GNFT) | Rumor.io

Genfit

GNFT

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GNFT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

Genfit has ended its liver failure program due to an adverse event in a phase 2 trial.
The company reported first-half 2025 financial results, with cash and cash equivalents totaling €107.5 million as of June 30, 2025.
Genfit's Q2 earnings missed expectations, with an adjusted EPS of $(0.23) and sales of $40.443M, a 38.62% decline from the previous year.

Generated by AI

Sentiment

Of the messages about GNFT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	98.95% +17.31
Bearish	—	—	0% 0	1.05% -17.31

Bullish· Jun 30

$GNFT has potential for significant growth, with a market cap of $200m and potential for $12.5bn across 6 indications.
The company is poised to receive a milestone payment of up to EUR360m from Ipsen, with an estimated EUR40m expected.
$GNFT has seen strong buying activity, with a 22.47% price increase due to increased volume and higher closing prices compared to the open.

Bearish· Dec 17

$GNFT has been heavily shorted, with some investors blaming manipulation despite the company's positive news.
$GNFT's price has been impacted by market makers selling at the top and buying back cheaper shares, causing it to drop.
$GNFT's price has stalled after a rapid decline, with some investors attributing this to their own ownership of the stock.

Generated by AI

Topics

Of the messages about GNFT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	64.29%	11.27%
Analysts	0%	0%	0%	6.1%
Announcements	0%	0%	35.71%	77.46%
Controversies	0%	0%	0%	2.35%
Earnings	0%	0%	0%	2.82%
Macro	0%	0%	0%	0%

Announcements· Jun 30

Genfit's elafibranor achieved positive results in the Phase III ELATIVE trial for primary biliary cholangitis, a rare cholestatic liver disease.
The trial's success may lead to potential future milestone payments of up to EUR360m for Genfit, with an estimated EUR40m expected.
Genfit's stock price surged 23-29% pre-market following the announcement of the positive trial results.

Technical Analysis· Feb 10

$GNFT's price has been affected by a gap down, with the author buying back in at $5.84 and holding onto the shares.
The author believes $GNFT still has potential for a reversal, despite the recent dip.
A rising wedge pattern has been identified on the 3-minute chart for $GNFT.

Generated by AI

Community

Of the messages about GNFT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	13.04%	33.22%
Newcomers	100%	100%	86.96%	66.78%

Regulars· Jun 30

The Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis (PBC) showed positive results, with Ipsen and Genfit announcing a 47% composite endpoint of responders.
The partnership between Ipsen and Genfit could result in potential future milestone payments of up to EUR360m, with an estimated EUR40m expected, according to Kepler Chevreux.
Genfit's elafibranor has hit the primary goal of the pivotal PBC study, setting up a potential showdown with Intercept, with Ipsen and Genfit's stock prices reacting positively to the news.

Newcomers· Jun 30

$GNFT's Phase 3 trial for liver disease candidate elafibranor was successful, with the company announcing positive results from the trial.
Many users are considering or have taken a position in $GNFT, with some expressing regret over not holding onto the stock after the announcement.
The positive trial results have a positive readthrough to $CBAY, another company, according to some users.

Generated by AI

PARIS, July 08, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2026, and provided business updates.

2mo agoYahoo Finance

Also Discussed

Investors talking about GNFT also mention

#	Name	Attention
1	CBAY - CymaBay Therapeutics, Inc.	——
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	ICPT - Intercept Pharmaceuticals, Inc.	——
4	Inventiva S.A. American Depositary ReceiptIVA	0%-0.01
5	Innate Pharma S.A. Sponsored ADRIPHA	0%0
6	Galapagos NV American Depositary ReceiptGLPG	0%0
7	Galectin Therapeutics Inc.GALT	0.01%+0.01
8	DBV Technologies S.A. Sponsored ADRDBVT	0%new
9	Nanobiotix S.A. ADRNBTX	0%0
10	Cellectis S.A. ADRCLLS	0%0

Genfit S.A.

Location

Social

What share of all stock conversation is about GNFT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

Genfit has ended its liver failure program due to an adverse event in a phase 2 trial.
The company reported first-half 2025 financial results, with cash and cash equivalents totaling €107.5 million as of June 30, 2025.
Genfit's Q2 earnings missed expectations, with an adjusted EPS of $(0.23) and sales of $40.443M, a 38.62% decline from the previous year.

Generated by AI

Sentiment

Of the messages about GNFT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	98.95% +17.31
Bearish	—	—	0% 0	1.05% -17.31

Bullish· Jun 30

$GNFT has potential for significant growth, with a market cap of $200m and potential for $12.5bn across 6 indications.
The company is poised to receive a milestone payment of up to EUR360m from Ipsen, with an estimated EUR40m expected.
$GNFT has seen strong buying activity, with a 22.47% price increase due to increased volume and higher closing prices compared to the open.

Bearish· Dec 17

$GNFT has been heavily shorted, with some investors blaming manipulation despite the company's positive news.
$GNFT's price has been impacted by market makers selling at the top and buying back cheaper shares, causing it to drop.
$GNFT's price has stalled after a rapid decline, with some investors attributing this to their own ownership of the stock.

Generated by AI

Topics

Of the messages about GNFT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	100%	100%	64.29%	11.27%
Analysts	0%	0%	0%	6.1%
Announcements	0%	0%	35.71%	77.46%
Controversies	0%	0%	0%	2.35%
Earnings	0%	0%	0%	2.82%
Macro	0%	0%	0%	0%

Announcements· Jun 30

Genfit's elafibranor achieved positive results in the Phase III ELATIVE trial for primary biliary cholangitis, a rare cholestatic liver disease.
The trial's success may lead to potential future milestone payments of up to EUR360m for Genfit, with an estimated EUR40m expected.
Genfit's stock price surged 23-29% pre-market following the announcement of the positive trial results.

Technical Analysis· Feb 10

$GNFT's price has been affected by a gap down, with the author buying back in at $5.84 and holding onto the shares.
The author believes $GNFT still has potential for a reversal, despite the recent dip.
A rising wedge pattern has been identified on the 3-minute chart for $GNFT.

Generated by AI

Community

Of the messages about GNFT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	13.04%	33.22%
Newcomers	100%	100%	86.96%	66.78%

Regulars· Jun 30

The Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis (PBC) showed positive results, with Ipsen and Genfit announcing a 47% composite endpoint of responders.
The partnership between Ipsen and Genfit could result in potential future milestone payments of up to EUR360m, with an estimated EUR40m expected, according to Kepler Chevreux.
Genfit's elafibranor has hit the primary goal of the pivotal PBC study, setting up a potential showdown with Intercept, with Ipsen and Genfit's stock prices reacting positively to the news.

Newcomers· Jun 30

$GNFT's Phase 3 trial for liver disease candidate elafibranor was successful, with the company announcing positive results from the trial.
Many users are considering or have taken a position in $GNFT, with some expressing regret over not holding onto the stock after the announcement.
The positive trial results have a positive readthrough to $CBAY, another company, according to some users.

Generated by AI

Genfit

Social

Sep 22

Sentiment

Bullish· Jun 30

Bearish· Dec 17

Topics

Announcements· Jun 30

Technical Analysis· Feb 10

Community

Regulars· Jun 30

Newcomers· Jun 30

News

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Also Discussed

Genfit S.A.

Company Information

Location

News

GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates

Also Discussed

Social

Sep 22

Sentiment

Bullish· Jun 30

Bearish· Dec 17

Topics

Announcements· Jun 30

Technical Analysis· Feb 10

Community

Regulars· Jun 30

Newcomers· Jun 30